Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COLL NASDAQ:DOVA NASDAQ:EGRX NASDAQ:PRVB NASDAQ:VNDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOLLCollegium Pharmaceutical$37.32-4.5%$35.00$23.23▼$42.29$1.23B0.63413,714 shs412,936 shsDOVADova Pharmaceuticals$28.04$28.04$5.62▼$28.54$807.55M2.74499,313 shs35,036 shsEGRXEagle Pharmaceuticals$3.21+0.3%$3.33$1.50▼$3.87$41.69M0.836,132 shs3,293 shsPRVBProvention Bio$24.98$24.58$3.18▼$25.00$2.37B2.472.28 million shs218,200 shsVNDAVanda Pharmaceuticals$4.51-2.0%$4.60$3.81▼$5.55$271.81M0.74404,217 shs367,875 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOLLCollegium Pharmaceutical-4.45%-2.61%-1.43%+27.90%+3.09%DOVADova Pharmaceuticals0.00%0.00%0.00%0.00%0.00%EGRXEagle Pharmaceuticals+0.31%+5.94%+0.31%+33.75%-13.94%PRVBProvention Bio0.00%0.00%0.00%0.00%0.00%VNDAVanda Pharmaceuticals-1.96%-2.17%+3.44%0.00%-8.33%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOLLCollegium Pharmaceutical$37.32-4.5%$35.00$23.23▼$42.29$1.23B0.63413,714 shs412,936 shsDOVADova Pharmaceuticals$28.04$28.04$5.62▼$28.54$807.55M2.74499,313 shs35,036 shsEGRXEagle Pharmaceuticals$3.21+0.3%$3.33$1.50▼$3.87$41.69M0.836,132 shs3,293 shsPRVBProvention Bio$24.98$24.58$3.18▼$25.00$2.37B2.472.28 million shs218,200 shsVNDAVanda Pharmaceuticals$4.51-2.0%$4.60$3.81▼$5.55$271.81M0.74404,217 shs367,875 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOLLCollegium Pharmaceutical-4.45%-2.61%-1.43%+27.90%+3.09%DOVADova Pharmaceuticals0.00%0.00%0.00%0.00%0.00%EGRXEagle Pharmaceuticals+0.31%+5.94%+0.31%+33.75%-13.94%PRVBProvention Bio0.00%0.00%0.00%0.00%0.00%VNDAVanda Pharmaceuticals-1.96%-2.17%+3.44%0.00%-8.33%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOLLCollegium Pharmaceutical 3.00Buy$42.3313.43% UpsideDOVADova Pharmaceuticals 0.00N/AN/AN/AEGRXEagle Pharmaceuticals 0.00N/AN/AN/APRVBProvention Bio 0.00N/AN/AN/AVNDAVanda Pharmaceuticals 3.50Strong Buy$16.50265.85% UpsideCurrent Analyst Ratings BreakdownLatest VNDA, DOVA, EGRX, PRVB, and COLL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/21/2025VNDAVanda PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.008/11/2025COLLCollegium PharmaceuticalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$44.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOLLCollegium Pharmaceutical$707.01M1.66$11.81 per share3.16$7.10 per share5.26DOVADova Pharmaceuticals$10.35M78.02N/AN/A$2.71 per share10.35EGRXEagle Pharmaceuticals$257.55M0.16$8.03 per share0.40N/A∞PRVBProvention Bio$12.90M183.54N/AN/A$1.40 per share17.84VNDAVanda Pharmaceuticals$198.77M1.34N/AN/A$9.24 per share0.49Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOLLCollegium Pharmaceutical$69.19M$1.0435.886.20N/A5.13%97.28%13.87%11/6/2025 (Estimated)DOVADova Pharmaceuticals-$72.28M-$2.60N/AN/AN/A-544.09%-101.60%-67.21%N/AEGRXEagle Pharmaceuticals$35.64MN/A0.00∞N/AN/AN/AN/AN/APRVBProvention Bio-$113.57M-$1.53N/AN/AN/A-880.69%-103.36%-69.08%N/AVNDAVanda Pharmaceuticals-$18.90M-$1.13N/AN/AN/A-32.90%-12.89%-10.47%11/5/2025 (Estimated)Latest VNDA, DOVA, EGRX, PRVB, and COLL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/31/2025Q2 2025VNDAVanda Pharmaceuticals-$0.34-$0.46-$0.12-$0.46$54.77 million$52.59 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOLLCollegium PharmaceuticalN/AN/AN/AN/AN/ADOVADova PharmaceuticalsN/AN/AN/AN/AN/AEGRXEagle PharmaceuticalsN/AN/AN/AN/AN/APRVBProvention BioN/AN/AN/AN/AN/AVNDAVanda PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOLLCollegium Pharmaceutical3.271.181.10DOVADova Pharmaceuticals0.415.645.37EGRXEagle PharmaceuticalsN/AN/AN/APRVBProvention Bio0.191.931.92VNDAVanda PharmaceuticalsN/A3.253.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOLLCollegium PharmaceuticalN/ADOVADova Pharmaceuticals33.03%EGRXEagle Pharmaceuticals85.36%PRVBProvention Bio37.39%VNDAVanda Pharmaceuticals88.14%Insider OwnershipCompanyInsider OwnershipCOLLCollegium Pharmaceutical2.51%DOVADova Pharmaceuticals60.30%EGRXEagle Pharmaceuticals28.90%PRVBProvention Bio13.10%VNDAVanda Pharmaceuticals10.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOLLCollegium Pharmaceutical21031.50 million30.71 millionOptionableDOVADova Pharmaceuticals11528.80 millionN/AOptionableEGRXEagle Pharmaceuticals10012.99 million9.23 millionNo DataPRVBProvention Bio8294.78 million82.37 millionNot OptionableVNDAVanda Pharmaceuticals29059.09 million53.18 millionOptionableVNDA, DOVA, EGRX, PRVB, and COLL HeadlinesRecent News About These CompaniesWellington Management Group LLP Cuts Stock Holdings in Vanda Pharmaceuticals Inc. $VNDASeptember 2, 2025 | marketbeat.comNuveen LLC Acquires Shares of 440,561 Vanda Pharmaceuticals Inc. $VNDASeptember 1, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Has $2.18 Million Stake in Vanda Pharmaceuticals Inc. $VNDASeptember 1, 2025 | marketbeat.comVanda: Next Phase Of Fanapt Growth Might Be With Bysanti AdvancementAugust 29, 2025 | seekingalpha.comVanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia ...August 29, 2025 | finanznachrichten.deVanda Pharmaceuticals Announces Participation at September 2025 Investor ConferencesAugust 28, 2025 | prnewswire.comVanda Pharmaceuticals gets FDA orphan drug status for VGT-1849BAugust 28, 2025 | seekingalpha.comVanda Pharmaceuticals stock rises after FDA orphan drug designationAugust 28, 2025 | za.investing.comVanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia VeraAugust 28, 2025 | prnewswire.comVanda Pharmaceuticals treatment of polycythemia vera granted orphan designationAugust 27, 2025 | msn.comVanda Pharmaceuticals' (VNDA) Buy Rating Reaffirmed at HC WainwrightAugust 23, 2025 | marketbeat.comVanda seeks FDA Commissioner review of Hetlioz generic rulingAugust 22, 2025 | msn.comVanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz®August 21, 2025 | prnewswire.comVanda wins appeals court fight over FDA jet lag rulingAugust 19, 2025 | thepharmaletter.comTVanda Pharmaceuticals Shares Climb After Court Reverses FDA DecisionAugust 18, 2025 | msn.comVanda Pharmaceuticals shares rise after court overturns FDA denialAugust 18, 2025 | za.investing.comVanda Pharma Stock Rockets 9% After Federal Appeals Court Sets Aside FDA Action: Retail Expects Stock To Cross $5-MarkAugust 18, 2025 | msn.comIn a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag DisorderAugust 18, 2025 | prnewswire.comHC Wainwright Issues Pessimistic Outlook for VNDA EarningsAugust 16, 2025 | marketbeat.comHC Wainwright Has Bearish Forecast for VNDA Q4 EarningsAugust 15, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Has $4.27 Million Stock Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)August 15, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVNDA, DOVA, EGRX, PRVB, and COLL Company DescriptionsCollegium Pharmaceutical NASDAQ:COLL$37.32 -1.74 (-4.45%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$37.32 0.00 (0.00%) As of 09/12/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Dova Pharmaceuticals NASDAQ:DOVADova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure. It also develops DOPTELET for the treatment of chronic immune thrombocytopenia and chemotherapy-induced thrombocytopenia. Dova Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Durham, North Carolina.Eagle Pharmaceuticals NASDAQ:EGRX$3.21 +0.01 (+0.31%) As of 09/12/2025 03:16 PM EasternEagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.Provention Bio NASDAQ:PRVBProvention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.Vanda Pharmaceuticals NASDAQ:VNDA$4.51 -0.09 (-1.96%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$4.53 +0.02 (+0.44%) As of 09/12/2025 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
